Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt's lymphoma cell lines

Cell Cycle

Volumn 10, Issue 1, 2011, Pages 127-134

  Roberti, Annalisa ^a,b   Rizzolio, Flavio ^a,b   Lucchetti, Chiara ^a,b   De Leval, Laurence ^c   Giordano, Antonio ^a,b  

^a Temple University   (United States)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Burkitt's lymphoma; INK4a ARF locus; Proteasome inhibitors; Ubiquitin proteasome system (UPS)

Indexed keywords

ARF PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEASOME; UBIQUITIN;

ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; DEREGULATION; DNA METHYLATION; EPIGENETICS; GENE INACTIVATION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN METHYLATION;

EID: 78650840614     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.1.14446     Document Type: Article

References (29)

1. Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest 2008; 26:306-16.
2. Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS 2008; 22:175-87. (Pubitemid 351380160)
3. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707-21.
4. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008; 27:6462-72.
5. Chen D, Shan J, Zhu WG, Qin J, Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 464:624-7.
6. ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001; 20:2171-7.
7. Ferry JA. Burkitt's lymphoma: Clinicopathologic features and differential diagnosis. Oncologist 2006; 11:375-83.
8. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533-8.
9. Jacobsen KA, Prasad VS, Sidman CL, Osmond DG. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice. Blood 1994; 84:2784-94.
10. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-69.
11. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13:2670-7.
12. Sharpless NE. INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 2005; 576:22-38.
13. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004; 23:379-85.
14. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
15. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378:115-77.
16. Sherr CJ. Parsing Ink4a/Arf: "Pure" p16-null mice. Cell 2001; 106:531-4.
17. Thielen C, Herens C, Fassotte MF, Detrooz E, Drion P, Diss T, et al. Establishment and characterisation of two novel human KSHV- and EBV-negative Burkitt cell lines, GAL-01 and GAL-02, from a primary lymphomatous effusion. Eur J Haematol 2006; 77:318-26.
18. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998; 91:1680-7.
19. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12:2424-33.
20. INK4a/MTS1 gene. Oncogene 1997; 15:2475-81.
21. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
22. Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 2002; 12:381-7.
23. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20:2423-35.
24. Schrader EK, Harstad KG, Matouschek A. Targeting proteins for degradation. Nat Chem Biol 2009; 5:815-22.
25. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004; 18:1862-74.
26. Ben-Saadon R, Fajerman I, Ziv T, Hellman U, Schwartz AL, Ciechanover A. The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue. J Biol Chem 2004; 279:41414-21.
27. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002; 3:49-55.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6.
29. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q, et al. Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006; 20:1602-9.